• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 15, 2017

View Archived Issues

Biopharma market too complex for simplistic pricing solutions

Note to U.S. policymakers and academics trying to bring down prescription drug prices: Biopharma is not a monolithic market, so simplistic or one-size-fits-all solutions could break the parts that are working well. Read More

Street coolish on AC effort as Aldeyra readies for FDA talks on design of phase III

Aldeyra Therapeutics Inc. CEO Todd Brady told BioWorld that the missed phase IIb primary endpoint with aldehyde trapper ADX-102 in allergic conjunctivitis (AC) was “retrofitted for another class of drugs [i.e., antihistamines], which is inactive after five to 10 minutes. We would have been viewed as having three eyes if we had picked something else as the main goal,” he said, adding that the outlook is likely “to change after the end-of-the phase II meeting” with the FDA. Read More

Medicxi’s $300M fund to help phase II assets reach potential

LONDON – Medicxi has launched a $300 million fund to invest in companies with phase II assets that need $100 million to move projects through phase III. That will help fill a clear gap in Europe, where it is practically impossible for growth-stage companies to get that sort of backing from local investors. Read More

Epizyme updates phase II data for tazemetostat

Interim data from Epizyme Inc.’s ongoing phase II trial of EZH2 inhibitor tazemetostat boosted company shares (NASDAQ:EPZM) Wednesday as investors embraced news that 92 percent of patients with relapsed or refractory follicular lymphoma and EZH2-activating mutations treated with the experimental therapy saw their tumors shrink. People with the same mutation and diffuse large B-cell lymphoma (DLBCL) also benefited, though at a lower rate than seen in an earlier preview of the data. Both cancers are forms of non-Hodgkin lymphoma. Read More

Putting the liver to work makes quick bispecifics

By treating mice with the messenger RNA (mRNA) encoding a bispecific antibody, rather than with the antibody itself, researchers from the German University of Mainz and Biontech AG have eliminated tumors in mice. In a direct comparison, the mRNA worked as well as the protein antibody did, and needed to be administered less often. Read More

With a majority stake in Ruide, Australia’s CSL becomes the Chinese market leader

HONG KONG – CSL Ltd. has bought a majority stake in China’s Wuhan Zhong Yuan Ruide Biological Products Co. Ltd. in a $352 million deal that should make the Australian biotech company a market leader. Read More

Financings

Orum Therapeutics, of Daejeon, South Korea, completed an $8 million series A financing with Intervest, KB Investment/Solidus Investment and LB Investment to advance its cell-penetrating antibody technology for the development of cancer therapeutics. Read More

Other news to note

Oxis International Inc., of Los Angeles, and Altor Bioscience Corp., of Miramar, Fla., agreed to collaborate exclusively in the development of a 161533 trispecific killer engager (Trike) fusion protein for cancer therapies. The Trike technology, developed by researchers at the University of Minnesota Masonic Cancer Center, was shown in nonclinical models to direct immune cells to kill cancer cells while diminishing drug-related toxicity. Read More

Appointments and advancements

Kempharm Inc., of Coralville, Iowa, named Andrew Barrett vice president, scientific affairs. Read More

In the clinic

Celltrion Inc., of Incheon, South Korea, said new data presented at the International Conference on Malignant Lymphoma and the European League Against Rheumatism congress 2017 demonstrate that CD20-targeting antibody CT-P10 is comparable to reference Rituxan (rituximab, Roche Holding AG/Biogen Inc.) in terms of efficacy and safety in both oncology and autoimmune disease indications. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe